More companies announce ARVO 2025 presentations

(Image credit: AdobeStock/Art_me2541)

As we near the final days before one of the biggest meetings in ophthalmology, more companies are announcing the presentation of their data at the event. The Association for Research in Vision and Ophthalmology 2025 Annual Meeting (ARVO 2025) is being held from May 4-8 in Salt Lake City, Utah.

Ophthalmology Times is onsite to cover the key data at this event. Be sure to stay tuned to our coverage for interviews with primary investigators and researchers who will be giving podium presentations at the event. Don’t forget to check our previously published list of companies with scheduled presentations.

Note: The following list of presentations is in alphabetical order by company. Updates may be added to this article as new information becomes available.

Astellas Pharma Inc.

The company is scheduled to highlight new data that enhances continued understanding of the science of geographic atrophy (GA), and the experience of patients living with the progressive disease at ARVO 2025. The data comprises 9 abstracts, including 2 oral presentations, featuring analyses on biomarkers, patient experience, mechanism of disease and other insights from the GATHER phase 3 studies of Izervay for the treatment of GA secondary to age-related macular degeneration.¹

Kodiak Sciences

Kodiak will have 7 scientific presentations on its research programs at the ARVO 2025 Annual Meeting, which will highlight the power and versatility of Kodiak's ABCD (Antibody Biopolymer Conjugate Drug) Platform for the design and development of new medicines for complex multifactorial diseases with a high unmet need. The presentations will center on the company’s research on ocular inflammatory disease and GA.²

Merit

Merit will present a poster at ARVO 2025 highlighting a potentially groundbreaking morphological end point. The poster, titled “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic Endpoint for Dry Age-Related Macular Degeneration,” will be presented on May 8, 2025. The company states that ORC represents a potential step forward for clinical end points in dry AMD (age-related macular degeneration), and specifically its late-stage form of GA. While GA lesion size is generally measured using fundus autofluorescence, ORC offers a new method derived from optical coherence tomography B-scans assisted by deep learning tools that is agnostic to the imaging device manufacturer.³

Reference:

1. Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses. News release. Astellas Pharma Inc. May 1, 2025. Accessed May 2, 2025. https://www.biospace.com/press-releases/astellas-to-present-new-data-in-geographic-atrophy-at-upcoming-ophthalmology-annual-congresses

2. Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases. News release. Kodiak Sciences. May 1, 2025. Accessed May 2, 2025. https://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Data+at+ARVO+2025+Highlight+Power+and+Versatility+of+ABC+Platform+in+Addressing+Complex+Multifactorial+Ocular+Diseases/24730377.html

3. MERIT to Showcase Novel Morphological Endpoint at ARVO 2025 Poster Presentation. News release. MERIT. May 1, 2025. Accessed May 2, 2025. https://www.westernslopenow.com/business/press-releases/ein-presswire/807759977/merit-to-showcase-novel-morphological-endpoint-at-arvo-2025-poster-presentation/